Gulf Pharmaceutical Industries (Julphar)
   HOME

TheInfoList



OR:

Julphar is an Emirati pharmaceutical manufacturer in the Middle East. Headquartered in Ras Al Khaimah, United Arab Emirates, the company employs more than 5,000 people and distributes its pharmaceutical products internationally. The company has three divisions — General Medicines, Julphar Diabetes Solutions and Julphar Life — with products having applications in Gastrology, Pain Management, Respiratory,
Wounds A wound is a rapid onset of injury that involves lacerated or punctured skin (an ''open'' wound), or a contusion (a ''closed'' wound) from blunt force trauma or compression. In pathology, a ''wound'' is an acute injury that damages the epider ...
and
Scars A scar (or scar tissue) is an area of fibrous tissue that replaces normal skin after an injury. Scars result from the biological process of wound repair in the skin, as well as in other organs, and tissues of the body. Thus, scarring is a natu ...
,
Gastrointestinal Tract The gastrointestinal tract (GI tract, digestive tract, alimentary canal) is the tract or passageway of the digestive system that leads from the mouth to the anus. The GI tract contains all the major organ (biology), organs of the digestive syste ...
,
Gynecology Gynaecology or gynecology (see spelling differences) is the area of medicine that involves the treatment of women's diseases, especially those of the reproductive organs. It is often paired with the field of obstetrics, forming the combined are ...
, Men's Health, Anemia, Anti-infectives, Neurology, Dermatology, Cardiology,
Dietary Supplements A dietary supplement is a manufactured product intended to supplement one's diet by taking a pill (pharmacy), pill, capsule (pharmacy), capsule, tablet (pharmacy), tablet, powder, or liquid. A supplement can provide nutrients either extr ...
and Vitamins. In 2018, the company was ranked as the number one pharmaceutical manufacturer in the UAE.


History

Julphar was established in 1980. The company obtained Ministry of Health approval for its first 30 products four years later and began manufacturing liquids and semi-solids in 1988. In 1990, distribution agents were established in key markets across the globe and work began on the construction of new manufacturing facilities in Ras Al Khaimah. Julphar II, III and IV were launched in 1998, a biotechnology plant, Julphar VII, was launched in 2003 and Julphar VIII, IX and X were launched in 2007. Julphar's transportation and shipping division, MenaCool, was launched in 2008 to transport the company's medicines across the MENA region. In 2011, Julphar crossed AED 1 billion in sales, an 11.3% growth from 2010. Julphar began producing biosimilars in 2012 and launched a new division, Julphar Diabetes Solutions, becoming the only company in the Middle East and North Africa to locally produce Recombinant DNA (r-DNA), the raw material used to make
insulin Insulin (, from Latin ''insula'', 'island') is a peptide hormone produced by beta cells of the pancreatic islets encoded in humans by the ''INS'' gene. It is considered to be the main anabolic hormone of the body. It regulates the metabolism o ...
. Julphar inaugurated its first facility on the African continent with the opening of Julphar Ethiopia in 2013. The launch of Julphar Bangladesh took place two years later in 2015, which coincided with the launch of Julphar Life, the company's consumer division. In 2017, Julphar acquired
IV fluid Intravenous therapy (abbreviated as IV therapy) is a medical technique that administers fluids, medications and nutrients directly into a person's vein. The intravenous route of administration is commonly used for rehydration or to provide nutrie ...
company, Gulf Inject and officially opened a facility in Saudi Arabia in collaboration with its local partner, Cigalah Group. In 2018, Julphar signed an agreement with the
Ministry of Health (United Arab Emirates) The Ministry of Health and Prevention (Arabic: ‘وزارة الصحة’ ) is the ministry of the Government of United Arab Emirates which is responsible for the implementation of health care policy in all areas of technical, material, and coord ...
to ensure the availability of critical medical supplies during crisis situations. Julphar won the Association of Strategic Alliance Professionals award in 2018 along with its partner, Merck & Co., becoming the first pharmaceutical company from the Middle East and Africa to win such an award. The company also won the Frost & Sullivan 2018 Best Emerging GCC Pharmaceutical Manufacturing Company of the Year award.


Facilities

Julphar has 16 production facilities.


Julphar UAE

Julphar UAE is based in Ras Al Khaimah and began operations in 1980. A total of 13 facilities produce tablets, capsules, pediatric powder suspensions (PPS), syrups, suspensions, vials, drops, ampoules, creams, ointments and suppositories.


Julphar Saudi Arabia

Julphar Saudi Arabia was launched in 2017 and is a joint venture between Julphar and its local partner, Cigalah Group. The facility was the first in King Abdullah Economic City to be awarded full
cGMP CGMP is an initialism. It can refer to: *cyclic guanosine monophosphate (cGMP) *current good manufacturing practice (cGMP) *CGMP, Cisco Group Management Protocol, the Cisco version of Internet Group Management Protocol The Internet Group Managem ...
certification on its first inspection by the Saudi Food and Drug Authority.


Products

One of Julphar's leading products is Moist Exposure Burn Ointment (MEBO), a common product used for burns. The success of MEBO led to the creation of MEBO Scar, an ointment which was developed specifically by Julphar for the treatment of scars both old and new, and is used to restore the health of traumatized skin. MEBO Scar is used to treat functional and cosmetic issues caused by scarring.


References

{{Reflist


External links


Company website
Pharmaceutical companies of the United Arab Emirates Multinational companies headquartered in the United Arab Emirates